formulations, conduct the bioavailability tests, and accurately record all observations and data.

Quality Control (QC): Ensure that all testing is performed in compliance with Good Laboratory Practices (GLP) and regulatory requirements, ensuring the reliability and reproducibility of the results.

Project Managers: Coordinate the bioavailability evaluation process, ensuring that timelines are met and resources are efficiently allocated.

4) Procedure

The following steps outline the procedure for evaluating the bioavailability of screening formulations:

1. Step 1: Define Formulation Requirements
   1. Identify the API and its pharmacokinetic profile, including solubility, permeability, and stability. This information is essential for designing the appropriate formulation and evaluating its bioavailability.
   2. Establish the formulation’s desired release profile (e.g., immediate release, sustained release, controlled release) based on therapeutic needs and the characteristics of the drug.
   3. Set acceptance criteria for bioavailability, such as the required minimum plasma concentration and the time to reach peak concentration (Tmax).
2. Step 2: Preparation of Formulation Samples
   1. Prepare the screening formulations, ensuring uniformity in API content and excipient composition. Formulations may include tablets, capsules, suspensions, or other oral dosage forms.
   2. Ensure the formulations are stable and meet quality control specifications before proceeding with bioavailability testing.
   3. Ensure that the formulations are compatible with the analytical methods to be used in the bioavailability evaluation (e.g., plasma sampling and analysis).
3. Step 3: Conduct Bioavailability Testing
   1. Animal Testing (Preclinical Stage):
      1. Administer the formulation to animal models (e.g., rats, dogs, monkeys) at the appropriate dose level and record the time of administration.
      2. Collect blood samples at various time points post-administration to measure the concentration of the API in plasma using validated analytical techniques (e.g., HPLC, LC-MS/MS).
      3. Monitor and record any adverse effects or signs of toxicity during the study period.
   2. Human Testing (Clinical Stage):
      1. If the formulation has passed preclinical bioavailability studies, proceed with human clinical trials to assess bioavailability in healthy volunteers or patients.
      2. Administer the formulation under controlled conditions, ensuring accurate dosing and timing.
      3. Collect blood samples at designated time intervals and measure the API concentration in plasma to evaluate the pharmacokinetic profile (e.g., Cmax, Tmax, AUC).
4. Step 4: Analyze Bioavailability Data
   1. Use pharmacokinetic software to calculate key bioavailability parameters, such as the area under the curve (AUC), maximum concentration (Cmax), time to maximum concentration (Tmax), and elimination half-life (t½).
   2. Compare the bioavailability of the screening formulation with the reference formulation (if available) to assess whether the test formulation meets the desired pharmacokinetic profile.
   3. Analyze the absorption rate, distribution, metabolism, and excretion (ADME) of the API and assess whether the formulation is likely to achieve therapeutic concentrations in the bloodstream.
5. Step 5: Data Interpretation and Reporting
   1. Interpret the bioavailability data to determine whether the formulation meets the required pharmacokinetic criteria, including therapeutic plasma levels and drug release rates.
   2. Prepare a comprehensive report that includes all test data, statistical analysis, and conclusions. The report should also include any recommendations for formulation adjustments or further testing.
   3. Ensure that the report is reviewed and approved by the formulation and pharmacokinetic teams before moving forward with clinical trials or further formulation development.
6. Step 6: Sample Disposal
   1. Dispose of any remaining test formulations, blood samples, and analytical materials following safety protocols and environmental regulations.
   2. Ensure that hazardous materials are disposed of in designated chemical waste containers, in compliance with GLP and safety guidelines.

5) Documents

The following documents should be maintained during the bioavailability evaluation of screening formulations:

1. Bioavailability Study Protocol
2. Formulation Preparation Records
3. Bioavailability Test Results (Plasma Concentration Data)
4. Pharmacokinetic Analysis Reports
5. Bioavailability Summary Report
6. Sample Disposal Records

6) Abbreviations

• API: Active Pharmaceutical Ingredient
• GLP: Good Laboratory Practices
• HPLC: High-Performance Liquid Chromatography
• LC-MS/MS: Liquid Chromatography-Mass Spectrometry/Mass Spectrometry
• Tmax: Time to Maximum Concentration
• Cmax: Maximum Concentration
• AUC: Area Under the Curve

7) References

References to regulatory guidelines and scientific literature that support this SOP:

• FDA Guidance for Pharmaceutical Development
• USP <1088> on Bioavailability and Bioequivalence
• ICH E7: Clinical Evaluation of Bioavailability and Bioequivalence

8) Version

Version 1.0: Initial version of the SOP.

9) Annexure

Bioavailability Testing Results Template

Formulation ID	Cmax (ng/mL)	Tmax (hrs)	AUC (ng·hr/mL)	Half-life (hrs)	Stability Results